SCHEMBL2302602

SCHEMBL2302602

CCC(CC)n1c(O)nc2ncc(Cl)c(-c3cccc(O)c3)c21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
HSD17B1 P14061 5/20 0.35
HSD17B2 P37059 5/20 0.35
CYP17A1 P05093 2/20 0.34
GCGR P47871 1/20 0.34
ADORA1 P30542 2/20 0.34
PIK3CG P48736 2/20 0.33
PIK3CA P42336 2/20 0.33
PIK3CB P42338 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
PDE4B Q07343 1/20 0.33
FYN P06241 1/20 0.32
NR3C1 P04150 1/20 0.32
PGR P06401 1/20 0.32
DYRK1A Q13627 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2302530 0.91 DHFR (0.37) ADORA1CYP2C9DYRK1ADYRK1B
SCHEMBL2295854 0.90 GRIN2B (0.36) ADORA1
SCHEMBL2297601 0.90 RECQL (0.34) ESR1ESR2GCGRADORA2A
SCHEMBL2297388 0.89 JAK2 (0.38) GCGRADORA1
SCHEMBL2300115 0.87 TGFBR1 (0.35) DYRK1AMAPK1
SCHEMBL2299674 0.87 USP7 (0.35) ESR1ESR2
SCHEMBL2298966 0.87 JAK2 (0.40) GCGRADORA1ADORA2AFYNDYRK1A
SCHEMBL3398945 0.87 CDK8 (0.34) AURKA
SCHEMBL2299432 0.86 CYP17A1 (0.31) CYP17A1ADORA1CYP3A4ADORA2AADORA2B
SCHEMBL3397374 0.86 NR1H2 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS YANG ZHE (US) 2011-12-22 US claimed
EP-2244711-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Incorporated (US) 2010-11-03 EP claimed
US-20090253737-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED 2009-10-08 US claimed
WO-2009099594-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2009-08-13 WO claimed
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS YANG ZHE (US) 2011-12-22 US disclosed
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS YANG ZHE (US) 2011-12-22 US disclosed
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS YANG ZHE (US) 2011-12-22 US disclosed
US-7989469-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED (US) 2011-08-02 US disclosed
US-20090253737-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253737-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS TNNC1, TNNI3, TNNT2 ESR1 1982/4885ESR2 2154/4885HSD17B1 4107/4885
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS TNNC1, TNNI3, TNNT2 ESR1 1824/4885ESR2 1843/4885HSD17B1 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.